FDA report pains Boston Scientific

An internal FDA estimate of the dangers posed by a Boston Scientific pacemaker suggests that they may be far higher than earlier estimates had suggested. In the report, agency experts argue that the odds of the Contak Renewal short circuiting may be ten times higher than than its maker previously admitted. Boston Scientific acquired the pacemaker when it bought Guidant in a $27-billion deal. The news comes a day after The Wall Street Journal published a front-page piece suggesting that leading cardiac centers may be moving away from using the company's drug-coated stents.

- see this article from Bloomberg News